Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIMD Ainos	$0.48 -5.0%	$0.56	$0.40 ▼ $1.07	$10.54M	2.2	252,537 shs	415,549 shs
ARTV Artiva Biotherapeutics	$1.57 -1.9%	$2.05	$1.55 ▼ $17.31	$38.98M	N/A	171,824 shs	193,560 shs
VOR Vor Biopharma	$0.89 +60.5%	$0.35	$0.13 ▼ $1.80	$111.21M	-0.51	3.43 million shs	281.78 million shs
XCUR Exicure	$5.55 -3.5%	$9.77	$1.44 ▼ $36.00	$36.33M	3.71	556,240 shs	10,319 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIMD Ainos	-4.99%	-11.51%	-20.95%	-5.49%	-42.94%
ARTV Artiva Biotherapeutics	-1.88%	-6.55%	-20.30%	-50.32%	+156,999,900.00%
VOR Vor Biopharma	+60.53%	+315.89%	+412.97%	+18.21%	-22.61%
XCUR Exicure	-5.21%	-27.17%	-44.50%	-60.33%	+1,666.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIMD Ainos	0.9278 of 5 stars	0.0	4.0	0.0	1.5	1.7	0.6
ARTV Artiva Biotherapeutics	2.6017 of 5 stars	3.5	0.0	0.0	2.0	1.7	1.3
VOR Vor Biopharma	3.1854 of 5 stars	4.3	2.0	0.0	2.9	1.7	0.6
XCUR Exicure	2.0524 of 5 stars	0.0	4.0	4.7	3.8	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIMD Ainos	0.00	N/A	N/A	N/A
ARTV Artiva Biotherapeutics	3.00	Buy	$17.80	1,033.76% Upside
VOR Vor Biopharma	2.50	Moderate Buy	$7.06	692.94% Upside
XCUR Exicure	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AIMD, XCUR, VOR, and ARTV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
6/11/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$12.00
5/15/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $18.00
5/9/2025	VOR Vor Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	VOR Vor Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform	$6.00 ➝ $6.00
5/9/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/8/2025	VOR Vor Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/8/2025	VOR Vor Biopharma	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/8/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$7.00 ➝ $0.40
4/8/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIMD Ainos	$20K	500.52	N/A	N/A	$1.10 per share	0.44
ARTV Artiva Biotherapeutics	$250K	152.98	N/A	N/A	$7.68 per share	0.20
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	$500K	70.15	N/A	N/A	$1.12 per share	4.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIMD Ainos	-$14.86M	-$1.29	N/A	∞	N/A	N/A	-88.07%	-48.60%	8/4/2025 (Estimated)
ARTV Artiva Biotherapeutics	-$65.37M	N/A	0.00	N/A	N/A	N/A	-75.95%	-39.51%	8/7/2025 (Estimated)
VOR Vor Biopharma	N/A	-$1.51	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	-$9.70M	-$4.81	N/A	∞	N/A	N/A	-319.72%	-82.41%	8/11/2025 (Estimated)

Latest AIMD, XCUR, VOR, and ARTV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q1 2025	AIMD Ainos	N/A	-$0.21	N/A	-$0.21	N/A	$0.11 million
5/8/2025	Q1 2025	ARTV Artiva Biotherapeutics	-$0.68	-$0.83	-$0.15	-$0.83	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIMD Ainos	N/A	N/A	N/A	N/A	N/A
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIMD Ainos	0.84	2.00	1.91
ARTV Artiva Biotherapeutics	N/A	13.93	13.93
VOR Vor Biopharma	N/A	N/A	N/A
XCUR Exicure	N/A	4.45	4.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIMD Ainos	N/A
ARTV Artiva Biotherapeutics	N/A
VOR Vor Biopharma	97.29%
XCUR Exicure	42.82%

Insider Ownership

Company	Insider Ownership
AIMD Ainos	10.39%
ARTV Artiva Biotherapeutics	21.40%
VOR Vor Biopharma	2.90%
XCUR Exicure	3.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIMD Ainos	40	20.76 million	18.61 million	Not Optionable
ARTV Artiva Biotherapeutics	81	24.36 million	19.15 million	N/A
VOR Vor Biopharma	140	124.96 million	65.45 million	Not Optionable
XCUR Exicure	50	6.32 million	6.07 million	Not Optionable

AIMD, XCUR, VOR, and ARTV Headlines

Recent News About These Companies

Exicure (NASDAQ:XCUR) Stock Price Down 5.8% - Here's Why

June 18, 2025 | marketbeat.com

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

May 28, 2025 | businesswire.com

Exicure (NASDAQ:XCUR) Trading Down 4.5% - Here's Why

May 28, 2025 | marketbeat.com

Why Exicure Inc. (XCUR) Soared on Monday

April 22, 2025 | msn.com

Exicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myeloma

April 16, 2025 | pharmabiz.comP

Exicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100

April 15, 2025 | pharmabiz.comP

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

April 14, 2025 | businesswire.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...

April 11, 2025 | gurufocus.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

April 11, 2025 | investing.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

April 11, 2025 | businesswire.com

Wednesday’s Insider Moves: Top Buys and Sells in US Stocks

March 27, 2025 | investing.com

Exicure, Inc. Reports Full Year 2024 Financial Results

March 18, 2025 | gurufocus.com

Exicure secures Australian patent for cancer treatment

March 15, 2025 | investing.com

Exicure announces issuance of new patent in Australia

March 15, 2025 | markets.businessinsider.com

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

March 13, 2025 | gurufocus.com

Kuehn Law Encourages Investors of Exicure, Inc. to Contact Law Firm

January 27, 2025 | markets.businessinsider.com

Exicure announces purchase agreement with GPCR Therapeutics

January 24, 2025 | markets.businessinsider.com

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

January 22, 2025 | businesswire.com

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

January 22, 2025 | businesswire.com

When the Price of (XCUR) Talks, People Listen

January 21, 2025 | news.stocktradersdaily.comN

When (XCUR) Moves Investors should Listen

January 11, 2025 | news.stocktradersdaily.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

More Than a Monetary Metal: Silver's Case for Outperformance
By Jeffrey Neal Johnson | June 22, 2025
View More Than a Monetary Metal: Silver's Case for Outperformance
Which Analyst-Favorite Drone Stock Will Come Out on Top?
By Nathan Reiff | June 25, 2025
View Which Analyst-Favorite Drone Stock Will Come Out on Top?
3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
By Nathan Reiff | June 9, 2025
View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
Top Steel Picks for the Coming Infrastructure Boom
By Chris Markoch | June 25, 2025
View Top Steel Picks for the Coming Infrastructure Boom
Top 3 FOMO Stocks for 2025 With More Room to Run
By Dan Schmidt | June 9, 2025
View Top 3 FOMO Stocks for 2025 With More Room to Run

AIMD, XCUR, VOR, and ARTV Company Descriptions

Ainos NASDAQ:AIMD

$0.48 -0.03 (-4.99%)

As of 06/26/2025 04:00 PM Eastern

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

Artiva Biotherapeutics NASDAQ:ARTV

$1.57 -0.03 (-1.88%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.62 +0.05 (+3.18%)

As of 08:18 AM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Vor Biopharma NYSE:VOR

$0.89 +0.34 (+60.53%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.95 +0.06 (+6.97%)

As of 08:20 AM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Exicure NASDAQ:XCUR

$5.55 -0.20 (-3.48%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$5.72 +0.17 (+3.05%)

As of 08:06 AM Eastern

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time